Patients were randomly allocated into three groups to receive ondansetron ( 4mg ; group A , n = 55 ) , ondansetron ( 8mg ; group B , n = 54 ) , or ramosetron ( 0.3 mg ; group C , n = 51 ) intravenously at the time of dural closure .